Updates

August 13, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers B(SaYnMdrBaO KLu:r TlaH CYoRmOpCleAxR, E ) (DSaClRalI PS tCreOeDt,E : 539871) B andra (E), Mumbai - 400051 Mumbai- 400001 Sub: General Update on disclosures pursuant to Regulations 29(2), 31(2) and 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as received from Docon Technologies Private Limited Ref: Release of pledge on 1,75,00,000 equity shares of Thyrocare Technologies Limited Dear Sir/Madam, We wish to inform you that the Company has received a communication dated August 13, 2026 from Docon Technologies Private Limited, Promoter of the Company, informing about t he release of pledge on 1,75,00,000 equity shares of Thyrocare Technologies Limited (“Company”) held by Docon Technologies Private Limited. T he said pledge was released by Catalyst Trusteeship Limited, acting as the Debenture Trustee, on August 11, 2026. In this regard, Docon Technologies Private Limited has submitted the requisite disclosures p ursuant to Regulations 29(2), 31(2) and 31(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. A copy of the disclosure received from Docon Technologies Private Limited is enclosed herewith for your information and taking the same on record. T hyrocare Technologies Limited, Yours Faithfully, Brijesh Kumar Company Secretary and Compliance Officer Encl. A/a DOCON TECHNOLOGIES PRIVATE LIMITED August 13, 2026 To, To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Phiroze Jeejeebhoy Towers, Block G, Bandra Kurla Complex, Dalal Street, Mumbai-400001 Bandra (E), Mumbai - 400051 Thyrocare Technologies Limited D37/ 3, TTC MIDC, Turbhe, Navi Mumbai - 400 073 Sub: Release of Pledge on 1, 75,00,000 equity Shares of Thyrocare Technologies Limited Ref: Disclosures pursuant to Regulations 29(2), 31(2) and Regulation 31(3) of the Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Dear Sir & Madam, We refer to our earlier disclosures dated September 24, 2025, November 11, 2025, December 05, 2025, March 31, 2026 and April 20, 2026 made under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI SAST Regulations"), in respect of the encumbrance created by Docon Technologies Private Limited ("Docon"), Promoter of Thyrocare Technologies Limited ("the Company"/ "Thyrocare"), in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee in connection with the secured, unlisted, Non-Convertible Debentures ("NCDs) issued by API Holdings Limited, the holding company of Docon. Docon is a wholly-owned subsidiary of API Holdings Limited and is the promoter of the Company. Docon holds 9,69,69,696 equity shares, representing 60.92% of the equity share capital of the Company. The aforesaid shares were pledged in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee, as security for the NCDs issued by API Holdings Limited. As on the date of this disclosure, the outstanding principal amount of the aforesaid NCDs is INR 10,500 million. The shareholding and encumbered shareholding percentages stated in this disclosures are based on the shareholding as on August 11, 2026, being the date of release of pledge. We wish to inform you that the pledge on 1,75,00,000 equity shares of the Company has now been released by Catalyst Trusteeship Limited, acting as the Debenture Trustee on August 11, 2026. Accordingly, pursuant to Regulations 29(2), 31(2) and 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find enclosed the requisite disclosures in respect of the release of pledge on 1,75,00,000 equity shares of the Company, held by Docon, which were pledged in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee. The requisite disclosures are enclosed as under: 1. Disclosure under Regulation 29(2) of the SEBI (SAST) Regulations: Annexure I 2. Disclosure under Regulation 31(2) & (3) of the SEBI (SAST) Regulations: Annexure II You are requested to take the same on record For Docon Techsiologies Private Limited ,f!f .□.fY- " !" -~ L ,,.. 1~~ ff Madhuri Sudhir Sarangdhar Company Secretary CIN No: U72900MH2016PTC443000 Registered Office: D37/ 3, TIC Industrial Area, MIDC, Turbhe, Navi Mumbai, Thane, Maharashtra, India, 400705 Email Id: corporntesecretarial@docon.co.in I Telephone No.: 06364926900 DOCON TECHNOLOGIES PRIVATE LIMITED Annexure I Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Name of the Target Company (TC) Thyrocare Technologies Limited ('Thyrocare") Name(s) ofthe acquirer and Persons Acting in Acquirer: noocon Technologies Private Limited Concert (PAC) with the acquirer PAC: API Holdings Limited Whether the acquirer belongs to Yes Promoter/Promoter group Name(s) of the Stock Exchange(s) where the shares 1. BSE Limited ofTC are Listed 2. National Stock Exchange of India Limited Details of the acquisition/ disposal as follows Number % w.r.t. total % w.r.t. share /voting total diluted capital wherever share/votin applicable(*) g capital of the TC(**) Before the acquisition under consideration, holding of: a. nnshares carrying voting rights NIL NIL NIL b. nnshares in the nature of encumbrance 9,69,69,696 60.92 60.75 (pledge/ lien/ non disposal undertaking/ otl=leFs) c. Voting rights (VR) otherwise than by shares NIL NIL NIL d. Warrants/convertible securities/any other NIL NIL NIL instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) e. Total (a+b+c+d) 9,69,69,696 60.92 60.75 Details of acquisition/sale a. Shares carrying voting rights acquired/sold Nil Nil Nil b. VRs acquired /sold otherwise than by Nil Nil Nil shares C. Warrants/convertible securities/any other Nil Nil Nil d. instrument that entitles the acquirer to 1, 75,00,000 10.99 10.96 receive shares carrying voting rights in the TC (speeify l=lolding in eael=l eategoPy<) acquired/sold Sl=larns eneumbered / invoked/released by tl=le aeEtuireF) e. Total (a+b+c+/-d) 1,75,00,000 10.99 10.96 CIN No: U72900MH2016PTC443000 Registered Office: D37/ 3, TIC Industrial Area, MIDC, Turbhe, Navi Mumbai, Thane, Maharashtra, India, 400705 Email Id: corporntesecretarial@docon.co.in I Telephone No.: 06364926900 DOCON TECHNOLOGIES PRIVATE LIMITED ~fter the acquisition/sale, holding of: a. Shares carrying voting rights 1, 75,00,000 10.99 10.96 b. ##Shares encumbered witl:t tl:te aEE1l:liFeF 7,94,69,696 49.93 49.79 C. VRs otherwise than by shares Nil Nil Nil d. Warrants/convertible securities/any other Nil Nil Nil instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition e. Total (a+b+c+d} 9,69,69,696 60.92 60.75 Mode of acquisition/ sale (e.g. open market / off- Release of pledge over 1, 75,00,000 equity shares of market/ public issue/ rights issue/ preferential Thyrocare Technologies Limited held by Docon allotment/ inter-se transfer etc). Technologies Private Limited (Promoter of Thyrocare Technologies Limited), which had been pledged in favour of Catalyst Trusteeship Limited in connection with the existing Non-Convertible Debentures ("NCDs") issued by API Holdings Limited. Date of acquisition/ sale of shares/ VR or date of August 11, 2026 (Release of Pledge) receipt of intimation of allotment of shares, whichever is applicable Equity share capital/ total voting capital of the TC 15,91,65,315 Equity shares having face value of Rs. before the said acquisition/ sale 10 each Equity share capital/ total voting capital of the TC 15,91,65,315 Equity shares having face value of Rs. after the said acquisition/ sale 10 each Total diluted share/voti [Showing first 8,000 characters — download PDF for full document]